FISHMAN BARRY 4
4 · Medicus Pharma Ltd. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Medicus Pharma (MDCX) Director Barry Fishman Receives 50,000-Share Award
What Happened Barry Fishman, a director of Medicus Pharma Ltd. (MDCX), was granted a derivative award (option) to acquire 50,000 shares on June 3, 2026. The Form 4 reports an acquisition of 50,000 shares at $0.00 (derivative instrument), with a $0 total value shown on the filing. This is a compensation-style award rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (timely filing).
- Transaction type/code: A (Grant/Award — derivative).
- Amount: 50,000 shares (derivative option reported at $0.00).
- Vesting: Option vests quarterly in four equal installments over one year (per footnote F1).
- Shares owned after the transaction: Not specified in the provided filing excerpt.
- No immediate sale or cashless exercise reported.
Context This is a typical equity compensation grant to an insider (director). It does not represent an open-market purchase (which some investors view as a stronger bullish signal) nor a sale. The award vests over one year, so future reported transactions could occur as portions vest or are exercised.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-03+50,000→ 50,000 totalExercise: $0.36Exp: 2031-06-03→ Common Shares (50,000 underlying)
Footnotes (1)
- [F1]The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.